SEC INSIDER TRANSACTIONS

INCYTE CORP (INCY) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

INCY · INCYTE CORP

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 53 filings · fetched 2026-11-13T18:19:43Z

Recent reported activity

0purchase rows on this page

1sale rows on this page

194matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	85A	106.47	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,293A	90.56	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	1,642A	85.01	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,623A	83.58	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	3,023A	83.2	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	1,643A	80.5	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,864A	77.67	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,623A	74.78	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	9,459A	72.27	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,072A	71.93	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	3,148A	68.62	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,709A	61.76	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,284A	64.25	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	Mayes Patrick AOfficer · EVP & Chief Scientific Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 59,537 shares of common stock issuable pursuant to previously reported restricted stock units have not vested. F2 Options granted on January 18, 2024 and will vest monthly through July 14, 2027 F3 Options granted on July 15, 2024 and will vest monthly through July 15, 2028 F4 Options granted on July 14, 2023 and will vest monthly through July 14, 2027 F5 As of July 31st, 2026, the award is fully vested and exercisable. F6 Options granted on January 17, 2025 and will vest monthly through July 15, 2028 References:	M Exercise / conversionCommon Stock · Non-derivative	2,918A	61.18	Direct	Form 4 ↗0002079962-26-000013
2026-07-31Filed 2026-08-04	CAGNONI PABLO JOfficer · President, Global Head of R&D Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. References: F1	S Sale (market/private)Common Stock · Non-derivative	15,888D	119.7	Direct	Form 4 ↗0001205703-26-000023
2026-07-23Filed 2026-07-27	Heeson LeeOfficer · EVP, Head of Incyte Intl Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. F2 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. References: F2	A Award / grantPerformance Shares · Derivative	13,498A	0	Direct	Form 4 ↗0002039219-26-000008
2026-07-23Filed 2026-07-27	Heeson LeeOfficer · EVP, Head of Incyte Intl Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. F2 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. References: F1	A Award / grantEmployee Stock Option (right to buy) · Derivative	15,423A	0	Direct	Form 4 ↗0002039219-26-000008
2026-07-23Filed 2026-07-27	Morrissey Michael JamesOfficer · EVP, Head of Tech. Operations Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. F2 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. References: F2	A Award / grantPerformance Shares · Derivative	8,999A	0	Direct	Form 4 ↗0001780915-26-000010
2026-07-23Filed 2026-07-27	Morrissey Michael JamesOfficer · EVP, Head of Tech. Operations Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The July 23, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. F2 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. References: F1	A Award / grantEmployee Stock Option (right to buy) · Derivative	6,426A	0	Direct	Form 4 ↗0001780915-26-000010
2026-07-16Filed 2026-07-20	Hoffman Richard A.Officer · EVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 Including the July 16, 2026 grant, this includes an aggregate of 16,861 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. F3 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: References: F4	A Award / grantEmployee Stock Option (right to buy) · Derivative	31,923A	0	Direct	Form 4 ↗0002098091-26-000005
2026-07-16Filed 2026-07-20	Hoffman Richard A.Officer · EVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 Including the July 16, 2026 grant, this includes an aggregate of 16,861 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. F3 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: References: F3	A Award / grantPerformance Shares · Derivative	18,487A	0	Direct	Form 4 ↗0002098091-26-000005
2026-07-16Filed 2026-07-20	Hoffman Richard A.Officer · EVP & General Counsel Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 Including the July 16, 2026 grant, this includes an aggregate of 16,861 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. F3 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: References: F1, F2	A Award / grantCommon Stock · Non-derivative	7,395A	0	Direct	Form 4 ↗0002098091-26-000005
2026-07-16Filed 2026-07-20	Gardner David HOfficer · EVP, Chief Strategy Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 Including the July 16, 2026 grant, this includes an aggregate of 16,824 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. F3 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: References: F4	A Award / grantEmployee Stock Option (right to buy) · Derivative	31,923A	0	Direct	Form 4 ↗0002085970-26-000005
2026-07-16Filed 2026-07-20	Gardner David HOfficer · EVP, Chief Strategy Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 Including the July 16, 2026 grant, this includes an aggregate of 16,824 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. F3 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: References: F3	A Award / grantPerformance Shares · Derivative	18,487A	0	Direct	Form 4 ↗0002085970-26-000005
2026-07-16Filed 2026-07-20	Gardner David HOfficer · EVP, Chief Strategy Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 Including the July 16, 2026 grant, this includes an aggregate of 16,824 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. F3 Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: References: F1, F2	A Award / grantCommon Stock · Non-derivative	7,395A	0	Direct	Form 4 ↗0002085970-26-000005

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.